InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.011 -0.249 (-95.77%)+
Announcement
Release
19 Jun 2026 9:22AM
Price at Release
$0.260
Full Release
download
Summary
Cynata Therapeutics Limited announced the results of the CYP-004 Phase 3 SCUlpTOR trial for osteoarthritis of the knee, which showed no statistically significant differences between the active and control groups in achieving key endpoints such as the patient-acceptable symptom state and cartilage thickness loss. Despite a substantial reduction in knee pain from 3 to 24 months, the control group's unexpected pain reduction and lack of evidence for cartilage loss reduction were noted. The trial, funded by the Australian Government NHMRC and led by Professor David Hunter, highlighted Cynata's CYP-004 as an iPSC-derived MSC product for joint injection. Following these results, Cynata will explore further development options for its Cymerus technology.
Key Points
  • No safety concerns identified with similar adverse event profiles between groups.
  • No statistically significant differences in co-primary endpoints between active and control groups.
  • Substantial reduction in knee pain intensity at all timepoints from 3-24 months, but no significant differences between groups.
  • CYP-004 is an off-the-shelf iPSC-derived MSC product candidate for intra-articular injection.
  • The SCUlpTOR trial was a placebo-controlled Phase 3 trial by the University of Sydney.
  • The trial was led by Professor David Hunter, funded by the Australian Government NHMRC.
  • CEO Dr Kilian Kelly acknowledged the unexpected pain reduction in the control group.
  • No evidence of a reduction in cartilage loss was observed.
  • Company reviewing options for further development of Cymerus technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.